Microtech's Groundbreaking Atrial Microsensor Implantations in the U.S.

Introduction

Microtech, a subsidiary of Medinol, has made remarkable strides in the medical technology field by announcing the first atrial microsensor implantations in the United States. These implantations are part of a First in Human (FIH) study that aims to revolutionize cardiac pressure monitoring.

Event Overview

On May 16, 2025, two patients undergoing Left Ventricular Assist Device (LVAD) surgery at New York-Presbyterian/Columbia University Irving Medical Center received these pioneering atrial-pressure microsensors. The surgical procedure was overseen by Dr. Koji Takeda, the Surgical Director of Adult Heart Transplant at the facility. This milestone is not only a significant achievement for Microtech but also a promising development in cardiac health care.

Technical Advancements

The Microtech atrial-pressure microsensor represents a new class of medical devices known for their diminutive size and passive functionality. Unlike traditional sensors that require batteries or antennas, these microsensors employ ultrasound technology to transmit and receive signals. This innovative feature enables the integration of the microsensors into existing medical devices, transforming them into multifunctional therapeutic-diagnostic tools that can monitor various parameters simultaneously.

Patient Benefits

The two patients who received the sensors at New York-Presbyterian/Columbia are part of a broader study that initially includes five microsensors implanted in Israel under similar conditions. According to Dr. Takeda, the implantation process is quick and minimally invasive, requiring only slight modifications to the existing LVAD procedures.

Dr. Nir Uriel, Director of Advanced Heart Failure and Cardiac Transplantation at NewYork-Presbyterian, emphasized the potential of these sensors to non-invasively monitor both left and right-sided cardiac pressures over extended periods. This capability is set to improve patient care by transitioning from symptom-based treatments to parameter-driven therapies. So far, pressure measurements have been consistent, accurate, and easily attainable for all study participants.

Future Implications

As part of the FIH study, approximately 15 patients are expected to be enrolled from the United States and Israel. Dr. Yoram Richter, CEO of Medinol, expressed optimism regarding the progress of the study and the microsensors' performance. He hopes to demonstrate the feasibility, usability, and accuracy of this innovative system, which aims to redefine cardiac health care.

Microtech is also exploring the integration of microsensors into existing medical devices, thereby broadening the scope of this pioneering technology.

About Medinol

Medinol is dedicated to redefining the landscape of disease diagnosis and treatment. By designing cutting-edge devices for vascular interventions and enhancing the efficacy of real-time health monitoring through implantable sensors, Medinol is committed to reshaping the future of medical technology. They collaborate with healthcare professionals and industry partners to engineer devices that not only meet current needs but also anticipate future advancements.

For more insights about Medinol and its innovative solutions, visit Medinol's Website or contact Chief Commercial Officer Jeff Roach via email.